Recursion Pharmaceuticals

Recursion Pharmaceuticals FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Recursion Pharmaceuticals (RXRX) as of Nov 11, 2026 is 58.67 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 80.42 % — a change of -27.04% (lower).

FCF Conversion

58.67 %

YoY

-27.04%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Recursion Pharmaceuticals is 2025 58.67 % . FCF Conversion Rate (FCF/EBITDA) of Recursion Pharmaceuticals was 2024 80.42 % . It decreases by -27.04% lower compared to the previous year.

The Recursion Pharmaceuticals FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
97.48 USD
Jan 1, 2020
59.92 USD
Jan 1, 2021
111.42 USD
Jan 1, 2022
50.49 USD
Jan 1, 2023
91.36 USD
Jan 1, 2024
80.42 USD
Jan 1, 2025
58.67 USD
The Recursion Pharmaceuticals FCF Conversion history
YEARFCF ConversionYoY
58.67 %-27.04%
80.42 %-11.98%
91.36 %+80.96%
50.49 %-54.69%
111.42 %+85.95%
59.92 %-38.53%
97.48 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Recursion Pharmaceuticals Stock analysis

What does Recursion Pharmaceuticals do? Recursion Pharmaceuticals, Inc. makes money by developing novel therapeutics through its Recursion Operating System (OS), which integrates automation, artificial intelligence, machine learning, and in vivo validation. The company focuses on discovering medicines using advanced technologies in biology, chemistry, automation, and computer science. Its clinical programs include REC-994, REC-2282, REC-4881, and REC-3964, with REC-994 being an orally bioavailable, superoxide scavenger small molecule for treating cerebral cavernous malformations. The company generates revenue from its platform and clinical development efforts, targeting biopharmaceutical partnerships and potential future drug sales. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, leveraging its Recursion Data Universe to map biological and chemical relationships. The Recursion Operating System (OS) enables the company to rapidly translate silico hypotheses into validated insights and novel chemistry through iterative loops of wet lab biology and chemistry data. The company's platform integrates physical and digital components to create virtuous cycles, driving the discovery of novel therapeutics. Revenue is derived from its technology platform and clinical programs, with potential partnerships in the biopharmaceutical sector. The company's primary products are its Recursion Operating System (OS) and clinical programs such as REC-994, REC-2282, REC-4881, and REC-3964. REC-994 is a small molecule designed for cerebral cavernous malformations, while the other programs are part of its broader therapeutic pipeline. The company targets biopharmaceutical companies and research institutions as potential partners for its technology and drug development services. Recursion Pharmaceuticals, Inc. monetizes its platform through licensing agreements and collaborative research deals, focusing on the discovery of novel medicines using AI-driven approaches. Recursion Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Recursion Pharmaceuticals stock

FCF Conversion Rate (FCF/EBITDA) of Recursion Pharmaceuticals is 58.67 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Recursion Pharmaceuticals changed from 80.42 % to 58.67 %, representing a -27.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Recursion Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Recursion Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Recursion Pharmaceuticals

All Key Metrics — Recursion Pharmaceuticals